The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
reported to the Securities and Exchange Commission (SEC)
by insider Yachmetz Philip K since year 2005.
The trader's CIK number is 1250318.
At the time of this reporting, Yachmetz Philip K is the EVP, Chief Business Officer of Savient Pharmaceuticals Inc .
(stock ticker symbol SVNT).
See this page for all insider trading activities at Savient Pharmaceuticals Inc .
Stock purchases, sales, and option exercises reported by insider Yachmetz Philip K since 2005.
Trade Date
Symbol
Company Name (Issuer)
Trade Type
Shares
Price ($)
Value ($)
2008-04-14
SVNT
Savient Pharmaceuticals Inc
Sale
3,785
19.00
71,919
2008-02-15
SVNT
Savient Pharmaceuticals Inc
Sale
2,361
20.01
47,232
2008-02-20
SVNT
Savient Pharmaceuticals Inc
Sale
2,455
20.01
49,113
2008-01-07
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
2.60
13,000
2008-01-08
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
2.42
12,100
2008-01-07
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
23.02
115,105
2008-01-08
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
23.15
115,759
2008-01-04
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
23.27
116,331
2008-01-02
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
2.42
12,100
2008-01-03
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
2.60
13,000
2008-01-02
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
23.47
117,330
2008-01-04
SVNT
Savient Pharmaceuticals Inc
Option Exercise
5,000
2.78
13,899
2008-01-03
SVNT
Savient Pharmaceuticals Inc
Sale
5,000
24.26
121,286
2007-12-10
SVNT
Savient Pharmaceuticals Inc
Sale
7,774
15.22
118,344
2007-04-12
SVNT
Savient Pharmaceuticals Inc
Sale
3,805
12.06
45,903
2007-03-05
SVNT
Savient Pharmaceuticals Inc
Sale
20,881
12.53
261,638
2007-02-15
SVNT
Savient Pharmaceuticals Inc
Sale
3,051
14.44
44,045
2006-04-12
SVNT
Savient Pharmaceuticals Inc
Sale
4,992
5.87
29,297
2005-05-18
SVNT
Savient Pharmaceuticals Inc
Purchase
10,000
3.18
31,780
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Yachmetz Philip K
(EVP, Chief Business Officer of Savient Pharmaceuticals Inc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.
